UBS Group AG Acquires 31,590 Shares of Dyne Therapeutics, Inc. $DYN

UBS Group AG increased its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 9.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 380,978 shares of the company’s stock after purchasing an additional 31,590 shares during the quarter. UBS Group AG’s holdings in Dyne Therapeutics were worth $7,452,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in DYN. AQR Capital Management LLC acquired a new stake in shares of Dyne Therapeutics during the first quarter valued at about $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Dyne Therapeutics by 5.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock valued at $597,000 after buying an additional 2,886 shares during the period. Goldman Sachs Group Inc. raised its holdings in Dyne Therapeutics by 58.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock valued at $10,407,000 after buying an additional 366,183 shares during the last quarter. Caxton Associates LLP bought a new position in Dyne Therapeutics in the 1st quarter valued at approximately $157,000. Finally, Creative Planning boosted its position in Dyne Therapeutics by 23.8% during the 2nd quarter. Creative Planning now owns 14,541 shares of the company’s stock worth $138,000 after buying an additional 2,797 shares during the period. Institutional investors own 96.68% of the company’s stock.

Insider Buying and Selling

In related news, insider Douglas Kerr sold 1,564 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $18.36, for a total transaction of $28,715.04. Following the transaction, the insider directly owned 170,042 shares of the company’s stock, valued at $3,121,971.12. This trade represents a 0.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jason P. Rhodes sold 83,219 shares of the company’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $18.18, for a total transaction of $1,512,921.42. Following the completion of the sale, the director directly owned 7,962 shares of the company’s stock, valued at $144,749.16. The trade was a 91.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 1,559,462 shares of company stock valued at $29,814,746. 14.14% of the stock is owned by company insiders.

Dyne Therapeutics Price Performance

DYN stock opened at $16.54 on Tuesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. The company’s 50-day moving average is $18.36 and its 200-day moving average is $18.53. The stock has a market capitalization of $2.73 billion, a PE ratio of -5.14 and a beta of 1.08. Dyne Therapeutics, Inc. has a 1 year low of $8.06 and a 1 year high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same quarter last year, the company posted ($1.05) EPS. Equities research analysts expect that Dyne Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

DYN has been the subject of several analyst reports. Chardan Capital reaffirmed a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 9th. Morgan Stanley reduced their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. Evercore set a $33.00 price objective on Dyne Therapeutics in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Finally, JPMorgan Chase & Co. reduced their target price on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a report on Tuesday, January 20th. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $35.00.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.